In this study, E.coli Nissle 1917 (EcN), an intestinal probiotic, was utilized as a targeted transport vector to deliver p53 and Tum-5 protein to tumor hypoxic regions. The tumor-targeting characteristics of EcN were investigated using luciferase Lux CDABE operon, and the results demonstrated that EcN could specifically accumulate in the solid
Here we asked whether the daily oral administrations of the probiotic Escherichia coli strain Nissle 1917 (ECN) might affect the outcome of the papain protease induced allergic lung inflammation

Escherichia coli Nissle (EcN) 1917 is a beneficial bacterial strain that has been used for certain GI conditions including diarrhea and ulcerative colitis EcN has been shown to have benefits in the intestinal tract. The product that contains EcN 1917 is called Mutaflor originally from Germany and has shown to be beneficial in patients with

Here we analyzed the impact of the gut microbiome on tumor colonization and tumor therapy by the Escherichia coli Nissle 1917 (EcN) strain. This EcN strain is a promising cancer therapy candidate with probiotic properties. In our study,
As a proof-of-concept study, we chose a well-known probiotic bacterium, Escherichia coli Nissle 1917 (EcN), a host bacterium which has been used for treating gastrointestinal disorders and solid

Increased numbers of adherent invasive Escherichia coli (AIEC) have been found in Crohn's disease (CD) patients. In this report, we investigate the potential of the probiotic Escherichia coli Nissle 1917 (EcN) to reduce features associated with AIEC pathogenicity in an already established infection with AIEC reference strain LF82.

U365.
  • qdd042654s.pages.dev/62
  • qdd042654s.pages.dev/238
  • qdd042654s.pages.dev/270
  • qdd042654s.pages.dev/94
  • qdd042654s.pages.dev/268
  • qdd042654s.pages.dev/9
  • qdd042654s.pages.dev/110
  • qdd042654s.pages.dev/178
  • qdd042654s.pages.dev/353

    • e coli nissle 1917 probiotic